SCHEMBL1781173

SCHEMBL1781173

Cc1nc(N)nc2c1C(=NOCCN(C)C)CC(c1ccco1)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 16/20 0.39
TDP1 Q9NUW8 7/20 0.39
MAPT P10636 6/20 0.39
LMNA P02545 8/20 0.39
TSHR P16473 6/20 0.39
MAPK1 P28482 6/20 0.39
HTT P42858 4/20 0.39
USP2 O75604 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
NPSR1 Q6W5P4 5/20 0.35
SHMT2 P34897 1/20 0.34
POLB P06746 10/20 0.33
PKM P14618 10/20 0.33
L3MBTL1 Q9Y468 9/20 0.33
HSD17B10 Q99714 5/20 0.33
RECQL P46063 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12075139 1.00 ALDH1A1 (0.39) ALDH1A1TDP1MAPTLMNATSHR
SCHEMBL1780678 0.84 ALDH1A1 (0.45) ALDH1A1TDP1MAPTLMNATSHR
SCHEMBL12075698 0.84 ALDH1A1 (0.45) ALDH1A1TDP1MAPTLMNATSHR
SCHEMBL12075115 0.81 HSP90AA1 (0.43) HSP90AA1HSP90AB1
SCHEMBL1781715 0.81 HSP90AA1 (0.43) HSP90AA1HSP90AB1
SCHEMBL12075354 0.80 HSP90AA1 (0.40) ALDH1A1KDM4EHSP90AA1HSP90AB1SMN1; SMN2
SCHEMBL1783869 0.80 HSP90AA1 (0.40) ALDH1A1KDM4EHSP90AA1HSP90AB1SMN1; SMN2
SCHEMBL1781164 0.80 ALDH1A1 (0.46) ALDH1A1TDP1MAPTLMNATSHR
SCHEMBL1781165 0.80 ALDH1A1 (0.46) ALDH1A1TDP1MAPTLMNATSHR
SCHEMBL3634966 0.76 SCN1A (0.37) ALDH1A1KDM4EHSP90AA1HSP90AB1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592430-B2 Quinazolin-oxime derivatives as Hsp90 inhibitors DAC SLR (IT) 2013-11-26 US claimed
EP-2144889-B1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2012-08-29 EP claimed
US-20110118258-A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2011-05-19 US claimed
US-8592430-B2 Quinazolin-oxime derivatives as Hsp90 inhibitors DAC SLR (IT) 2013-11-26 US disclosed
EP-2144889-B1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2012-08-29 EP disclosed
US-20110118258-A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2011-05-19 US disclosed
EP-2144889-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC S.r.l. (IT) 2010-01-20 EP disclosed
WO-2008142720-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118258-A1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 ALDH1A1 1998/4885TDP1 287/4885MAPT 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.